Welcome to our dedicated page for Genmab news (Ticker: GMAB), a resource for investors and traders seeking the latest updates and insights on Genmab stock.
Genmab A/S develops antibody medicines for cancer and other serious diseases through therapeutic formats that include bispecific antibodies, antibody-drug conjugates, immune-modulating antibodies and other next-generation modalities. Company news commonly centers on clinical data, regulatory interactions and portfolio decisions for programs such as EPKINLY®/epcoritamab, rinatabart sesutecan (Rina-S®) and petosemtamab.
Recurring updates also cover collaborations and commercialization economics tied to antibody products, including DARZALEX® royalties under the Johnson & Johnson license, EPKINLY development with AbbVie, research partnerships, and capital or shareholder announcements. Genmab’s disclosures frequently connect pipeline progress with hematologic malignancies, solid tumors and the company’s broader antibody-technology strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Genmab A/S (Nasdaq: GMAB) announced the submission of a Japan New Drug Application (JNDA) for epcoritamab, an investigational bispecific antibody targeting relapsed/refractory large B-cell lymphoma (LBCL). This submission is backed by results from Japanese and global phase 2 clinical trials. Epcoritamab's ongoing development involves collaboration with AbbVie, with shared responsibilities for commercialization in the U.S. and Japan. The treatment shows promise as a therapeutic option for patients requiring alternative therapies.
Genmab A/S (Nasdaq: GMAB) has announced promising results from multiple clinical trials involving epcoritamab, an investigational bispecific antibody targeting B-cell malignancies. Notable findings include an 85% overall response rate in a phase 1b/2 trial for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high response rates in follicular lymphoma. Epcoritamab is co-developed with AbbVie and is undergoing regulatory review, with an FDA action date of May 21, 2023. The breadth of data presented at the American Society of Hematology annual meeting underscores Genmab's commitment to addressing critical treatment needs.
Genmab (NASDAQ: GMAB) announced the acceptance of 19 abstracts for the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, showcasing investigational therapies including epcoritamab. The data will feature four oral presentations on epcoritamab's efficacy in treating various B-cell malignancies. The company will present early data on GEN3014 and GEN3017. A 2022 R&D Update and ASH Data Review meeting is scheduled for December 12.